Results 91 to 100 of about 31,122 (181)
Role of cardiac imaging in Anderson-Fabry cardiomyopathy
The Anderson-Fabry disease (AFD, or simply Fabry Disease, FD; MIM #301500) is a rare X-linked lysosomal storage disorder (Xq22.1) characterized by progressive renal failure, leading to morbidity through cardio- and cerebro-vascular involvement.
Walter Serra, Nicola Marziliano
doaj +1 more source
Anderson-Fabry disease (AFD) is an X-linked lysosomal storage disorder caused by a deficiency of alpha-galactosidase A. Approximately 50% of patients with AFD may have cardiac involvement.
Shusuke Kasuya +7 more
doaj +1 more source
Inter-familial and intra-familial phenotypic variability in three Sicilian families with Anderson-Fabry disease. [PDF]
BACKGROUND: Anderson-Fabry disease (AFD) is an inborn lysosomal enzymopathy resulting from the deficient or absent activity of the lysosomal exogalactohydrolase, α-galactosidase A.
DAIDONE, Mario +14 more
core +1 more source
Biomarkers and Imaging Findings of Anderson–Fabry Disease—What We Know Now
Anderson–Fabry disease (AFD) is an X-linked lysosomal storage disorder, caused by deficiency or absence of the alpha-galactosidase A activity, with a consequent glycosphingolipid accumulation.
Idalina Beirão +6 more
doaj +1 more source
Abstracts of the 18th SCWD Conference, 11‐13 December 2025 in Rome/Italy
JCSM Communications, Volume 9, Issue 1, January/June 2026.
wiley +1 more source
Gene Editing in Fabry Disease: A Strategy Delineation
Oral presentation by first authorThe use of iPSCs, in the last years became wide spread, even in our group at INSA, the use of iPSCs to develop models of disease is now envisaged for various Lysosomal Storage Diseases.
Moreira, Luciana +3 more
core
Cardiovascular comorbidities in Anderson-Fabry disease: prevalence and clinical significance
reservedBackground: Anderson–Fabry disease (AFD) is a rare X-linked lysosomal storage disorder caused by GLA gene mutations leading to α-galactosidase A deficiency.
GATTARI, BIANCA MARIA
core
Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy
AIMS: Anderson-Fabry disease affects various organ systems due to glycosphingolipid accumulation. Enzyme replacement therapy (ERT) has been reported to decrease left ventricular wall thickening (LVWT) and to improve diastolic dysfunction.
C. H. Attenhofer Jost +23 more
core +1 more source
Little is known about regional longitudinal strain (LS) distribution in early stages of Anderson-Fabry disease (AFD) cardiomyopathy. We investigated regional left ventricular (LV) patterns of LS strain and base-to-apex behaviour of LS in treatment-naïve
Galderisi, Maurizio +12 more
core +1 more source

